Knowledge Gained for Treatment of Metastatic Hormone-Sensitive Prostate Cancer

An educational activity provided by i3 Health has produced knowledge gains and expertise regarding the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In the United States, prostate cancer is the most common tumor type affecting men. The American Cancer Society estimated for 2022 that there will be 268,490 new cases diagnosed, with 34,500 of these cases resulting in death. Most patients with mHSPC present with relapse after local treatment, while approximately 5% of all p...

Continue reading

Significant Knowledge Gains Acquired for Treating Metastatic Breast Cancer

An educational enduring online activity provided by i3 Health has provided knowledge gains pertaining to enhancing treatment tolerability, adherence, and patient-centered care for metastatic breast cancer. In the United States, breast cancer accounts for approximately 30% of cancer diagnoses among women and is the second-leading cause of cancer death. The American Cancer Society has estimated that in 2022 there will be 287,580 new cases of invasive breast cancer, with 43,250 of these cases resul...

Continue reading

Providing Proficiency for Personalized Care Plans for Metastatic Colorectal Cancer

An educational enduring online activity provided by i3 Health has demonstrated knowledge gains pertaining to up-to-date treatment and personalized health care plans for metastatic colorectal cancer (CRC). Recently the American Cancer Society estimated that CRC would see 151,030 new cases, with 52,580 of these diagnoses being fatal, this year alone, making CRC the third most commonly diagnosed cancer in the United States. If found early, CRC can be and is often cured, with a 5-year survival rate ...

Continue reading

Upgrades in Understanding Therapeutic Strategies for Graft-Versus-Host Disease

An educational enduring online activity provided by i3 Health has provided efficiency and knowledge gains encompassing the evolving landscape of therapeutic strategies for graft-versus-host disease (GVHD). Graft-versus-host disease is a complication of allogeneic hematopoietic stem cell transplant (HSCT), affecting between 40% and 60% of patients and accounting for 15% of posttransplant mortality. Acute GVHD is the second-leading cause of transplant-related mortality and typically targets the sk...

Continue reading

Optimizing Proficiency for Treating Advanced Soft Tissue Sarcoma

An educational enduring online activity provided by i3 Health has demonstrated knowledge gains regarding the best treatment and management of advanced soft tissue sarcoma. Soft tissue sarcomas are a heterogeneous group of malignancies that arise primarily from the mesodermal tissues of the extremities, trunk and retroperitoneum, and head and neck. The American Cancer Society estimated that 13,190 new cases will be diagnosed in the United States in 2022, and 5,130 of these cases are estimated to ...

Continue reading

Accomplishing Knowledge Gains in the Diagnosis and Management of Myelodysplastic Syndromes

A learning opportunity provided by i3 Health has demonstrated significant knowledge gains regarding the latest advances in the treatment of myelodysplastic syndromes. These findings were presented at the 4th Annual Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit.

Continue reading

Garnering Knowledge Gains for Treatment of Advanced Renal Cell Carcinoma

An educational enduring live meeting series and online activity provided by i3 Health has demonstrated knowledge gains encompassing the nurse's perspective of evolving treatment paradigms in advanced renal cell carcinoma (RCC). Kidney cancer is among the top 10 most common cancers in the United States, accounting for approximately 4% of all cancer diagnoses in the US. The American Cancer Society predicted that in 2022, 79,000 new cases of kidney cancer would be diagnosed, with 13,920 of these ca...

Continue reading

Confronting Educational Needs in Treatment of Myelofibrosis

An educational live and enduring activity provided by i3 Health has demonstrated significant learning outcomes for the management and treatment of patients with myelofibrosis. Myelofibrosis, considered a form of chronic leukemia, is a rare type of myeloproliferative neoplasm. An estimated one-third of individuals who have myelofibrosis will not show any symptoms in the early stages of the disorder, which can last many years. However, as the disease develops, they will begin to exhibit symptoms s...

Continue reading

Expertise and Knowledge Gains Made for Treatment of Prostate Cancer

An educational live and enduring activity provided by i3 Health has demonstrated increased expertise and learning outcomes for treatment of patients with prostate cancer. Prostate cancer is the most common cancer in American men, seeing an average of 1 out of 8 men being diagnosed with it within their lifetime. The typical treatment for progressive prostate disease is androgen deprivation therapy (ADT); however, it is common for prostate cancer to become castration-resistant or resistant to ADT....

Continue reading

Closing Nurses’ Knowledge Gaps Regarding Treatment of Castration-Resistant Prostate Cancer

An educational live and enduring activity provided by i3 Health has demonstrated knowledge gains and learning outcomes for nurses treating patients with castration-resistant prostate cancer (CRPC). Prostate cancer is the most common tumor type in men, affecting one in eight men in the United States. The estimate for 2022 is expecting 268,490 new cases of prostate cancer, with 34,500 of those cases resulting in death. The typical treatment for progressive prostate disease is androgen deprivation ...

Continue reading

Conquering Knowledge Gaps Concerning Therapeutic Advances in T-Cell Lymphoma

A learning opportunity provided by i3 Health has demonstrated significant knowledge gains regarding therapeutic advances in T-cell lymphoma (TCL). T-cell lymphoma is a rare type of non-Hodgkin lymphoma with many different subtypes, including peripheral TCL, anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, angioimmunoblastic TCL, and cutaneous TCL. TCL makes up less than 15% of total non-Hodgkin lymphomas. Mycosis fungoides (MF), the most common form of cutaneous TCL, frequently mi...

Continue reading

Oncology Showdown Activity Tackles Proficiency in Treatment of Advanced Non-Hodgkin Lymphoma

An educational live and enduring activity provided by i3 Health has demonstrated significant learning outcomes for treatment of patients with advanced non-Hodgkin lymphoma (NHL). The live activity, which was presented virtually at the 4th Annual GLAONS Oncology Care Summit, used a competitive, team-based "game show" format to explore the latest strategies and expert perspectives in treatment of patients with advanced NHL, including subtypes of follicular lymphoma (FL) and chronic lymphocytic leu...

Continue reading

Supporting Educational Needs in Treatment of Advanced Non–Small Cell Lung Cancer

An educational enduring activity provided by i3 Health demonstrated significant learning outcomes in the selection of treatment for patients with anaplastic lymphoma kinase (ALK)–positive advanced non–small cell lung cancer (NSCLC). This activity was created to advise clinicians on the development of individualized treatment plans based on the best available evidence and emerging guideline recommendations. Lung cancer is the second most common cancer in the United States, and the first most dead...

Continue reading

Addressing Knowledge Gaps in the Treatment of Metastatic Colorectal Cancer

An educational activity provided by i3 Health has revealed significant learning gains in the knowledge of novel treatment strategies for metastatic colorectal cancer (mCRC). The activity was presented virtually at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2020 and was made available as an enduring online activity. Colorectal cancer is the second leading cause of cancer death among women and men in the United States and is the third most diagnosed cancer worldwide. In the...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.